Hopp til hovedinnhold

Eggstokkreft, ovarialkreft

Sist oppdatert: Sist revidert:
Sist revidert av:
Definisjon:
Inndeles grovt i epitelial og ikke-epitelial ovarialkreft. Hovedsaklig ukjent årsak, hormonell påvirkning spiller sannsynligvis en rolle. Arv er medvirkende årsak hos 10%
Forekomst:
Den tredje hyppigste gynekologiske kreftformen i Norge med rundt 500 nye tilfeller årlig. Hyppigst blant kvinner i 50-60 årene
Symptomer:
Ofte få, uspesifikke, symptomer. Ukarakteristiske abdominalplager, vaginalblødning, endret avføringsmønster, nedsatt matlyst og følelse av oppfylthet kan inntreffe. 3 av 4 har spredning utenfor det lille bekkenet på diagnosetidspunktet
Funn:
Kliniske funn er ev. palpabel, hard, uregelmessig, fiksert tumor i adnex
Diagnostikk:
Diagnosen stilles ved gynekologisk undersøkelse med ultralyd, supplert med blodprøver og bildeundersøkelser. Histologisk undersøkelse.
Behandling:
Kirurgi er hovedbehandlingen. Kjemoterapi gis ofte som tilleggsbehandling. Ev. VEGF-hemmer, PARP-hemmer i utvalgte situasjoner.
  • Nasjonal behandlingstjeneste for avansert bekkeneksenterasjon ved gynekologisk kreft, Oslo universitetssykehus HF, nettsted 
  • Nasjonal behandlingstjeneste for fertilitetsbevarende behandling med autologt ovarialvev, Oslo universitetssykehus HF, nettsted 
  • Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for gynekologisk kreft. Eggstokkreft, tubekreft og bukhinnekreft. 28.06.2021. Siden besøkt 11.11.2021
  1. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for gynekologisk kreft. Eggstokkreft, tubekreft og bukhinnekreft. 28.06.2021. Siden besøkt 11.11.2021 helsedirektoratet.no  
  2. Doubeni CA, Doubeni ARB, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Physician. 2016 Jun 1;93(11):937-944.
  3. Kreftregisteret. Cancer in Norway 2020. Oslo: Kreftregisteret, 2021. www.kreftregisteret.no. www.kreftregisteret.no  
  4. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183–203.
  5. Pruthi S, Gostout BS, Lindor NM. Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clin Proc. 2010;85(12):1111–1120.
  6. Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol. 2012;55(1):3–23.
  7. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329–1333.
  8. Jordan SJ1, Whiteman DC, Purdie DM, Green AC, Webb PM. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol 2006; 103: 1122-9. pmid:17005245 PubMed  
  9. Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjær S, Lidegaard Ø. Hormon therapy and ovarian cancer. JAMA 2009; 302: 298-305. Journal of the American Medical Association  
  10. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015. doi:10.1016/S0140-6736(14)62458-2 DOI  
  11. Rizzuto I, Behrens RF, Smith LA. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database of Systematic Reviews 2019, Issue 6. Art. No.: CD008215. DOI: 10.1002/14651858.CD008215.pub3. Accessed 03 December 2021. The Cochrane Library  
  12. Michels KA, Pfeiffer RM, Brinton LA, et al. Modification of the Associations Between Duration of Oral Contraceptive Use and Ovarian, Endometrial, Breast, and Colorectal Cancers. JAMA Oncol 2018. doi:10.1001/jamaoncol.2017.4942 DOI  
  13. Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31(33):4188–4198.
  14. Iversen L, Fielding S, Lidegaard Ø, et al. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study BMJ 2018; 362 :k3609. DOI: 10.1136/bmj.k3609. DOI  
  15. Kjaer SK, Mellemkjaer L, Brinton LA, Johansen C, Gridley G, Olsen JH. Tubal sterilization and risk of ovarian, endometrial and cervical cancer: a Danish population-based follow-up study of more than 65 000 sterilized women. Int J Epidemiol 2004; 33: 596-602. PubMed  
  16. Menon U, Gentry-Maharaj A, Burnell M et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021 Jun 5;397(10290):2182-2193. Epub 2021 May 12. PMID: 33991479 PubMed  
  17. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295–2303.
  18. Henderson JT., Webber EM., Sawaya GF.. Screening for Ovarian Cancer Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2017; 319: 595-606. doi:10.1001/jama.2017.21421 DOI  
  19. Paulsen T, Kærn J, Kjærheim K, Tropé C, Tretli S. Symptoms and referral of women with epithelial ovarian tumors. Int J Gynaecol Obstet 2005;88(1):31–7. PMID: 15617702. PubMed  
  20. Baun ML, Jensen H, Falborg AZ et al. Ovarian cancer suspicion, urgent referral and time to diagnosis in Danish general practice: a population-based study. Fam Pract. 2019 Nov 18;36(6):751-757. PMID:31046091. PubMed  
  21. Liu JH, Zanotti KM. Management of the adnexal mass. Obstet Gynecol. 2011;117(6):1413–1428.
  22. Barney SP, Muller CY, Bradshaw KD. Pelvic masses. Med Clin North Am 2008; 92: 1143-61. PubMed  
  23. Sevinc A, Adli M, Kalender ME, Camci C. Benign causes of increased serum CA-125 concentration. Lancet Oncol 2007; 8: 1054-5. PubMed  
  24. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–2529.
  25. Ameye L, et al. Clinically oriented three-step strategy for assessment of adnexal pathology. Ultrasound Obstet Gynecol. 2012;40(5):582–591.
  26. Timmerman D, Ameye L, Fischerova D, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ. 2010;341:c6839.
  27. Zhang S, Yu S, Hou W, et al. Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors. J Ovarian Res. 2019;12(1):87. Published 2019 Sep 16. PMID: 31526390. PubMed  
  28. Lawrie TA, Winter-Roach BA, Heus P, Kitchener HC. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2015, Issue 12. Art. No.: CD004706. DOI: 10.1002/14651858.CD004706.pub5 DOI  
  29. Stockler MR, Hilpert F, Friedlander M etal. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. Epub 2014 Mar 31. PMID: 24687829 PubMed  
  30. Morrison J, Haldar K, Kehoe S, Lawrie TA. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews 2012; 8: CD005343. DOI: 10.1002/14651858.CD005343.pub3. DOI  
  31. Rauh-Hain JA, Melamed A, Wright A. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer. JAMA Oncol 2017; 3(1): 76-82. pmid:27892998 PubMed  
  32. Melamed A, Fink G, Wright AA, et al. Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study. BMJ 2018; 360: j5463. doi:10.1136/bmj.j5463 DOI  
  33. Fung-Kee-Fung M1, Oliver T, Elit L. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007; 14: 195-208. pmid:17938703 PubMed  
  34. Mansoor R. Mirza, M.D., Bradley J et al.. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 2016. pmid:27717299 PubMed  
  35. Moore KN, Secord AA, Geller MA, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial published correction appears in Lancet Oncol. 2019 May;20(5):e242. Lancet Oncol. 2019;20(5):636-648. PMID: 30948273. PubMed  
  36. Mirza MR, Coleman RL, González-Martín A et al. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 2020 Jun 19:S0923-7534(20)39891-4. Epub ahead of print. PMID: 32569725. PubMed  
  37. Wiggans AJ, Cass GKS, Bryant A, Lawrie TA, Morrison J. Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database of Systematic Reviews 2015, Issue 5. Art. No.: CD007929. DOI: 10.1002/14651858.CD007929.pub3. Accessed 06 December 2021. The Cochrane Library  
  • Silje Folven Barlindhaug, spesialist i allmennmedisin, redaktør NEL

Tidligere fagmedarbeidere

  • Terje Johannessen, professor i allmennmedisin, Trondheim